Asia-Pacific region houses some of Galderma’s fastest growing markets, where sales have fueled a strong performance. There have been multiple successes in the region in 2024 for the Swiss pharmaceutical firm, with a number of important product launches, such as Restylane VOLYME in China, Restylane EYELIGHT in Korea and Alastin in Australia. More recently, Relfydess (RelabotulinumtoxinA) was approved in Australia and Sculptra - which celebrated its 25th launch anniversary this year - was approved...
Dr. Mohan Yadav discusses strategic investment opportunities with A&D Medical, highlighting Madhya Pradesh’s business-friendly policies, infrastructure incentives, and vision for advancing life sciences manufacturing in India. ...
Partnership highlights Scorpius’ expertise in supporting innovative therapeutic programs...
Series A funding boosts efforts to commercialize innovative healthcare solutions....
Collaboration explores groundbreaking applications in cellular communication and therapy. ...
New joint research initiative combines UCSF’s clinical and research expertise with GE HealthCare’s engineering innovation to improve diagnosis, enhance access to precision treatments, and drive breakthroughs in brain health, oncology, and imaging technology....
New capabilities provide deeper insights from biological sample analysis....
Merger combines ultra-sensitive blood and tissue protein analysis into a unified platform. ...
Empowering healthcare and life sciences with faster insights, streamlined data mining, and AI-driven innovation....
With first ARGO HT installation at Hong Kong Center for Neurodegenerative Diseases...
![[L-R]: Ms. Vivien Tan, XP Business Manager, Siemens Healthineers ASEAN; Prof. Dr. dr. Lina Choridah, Sp.Rad (K), Chairwoman Indonesian Woman Imaging Society; Hendya Perbangkara, Head of Diagnostic Imaging, Siemens Healthineers Indonesia](/uploads/articles/l_r__ms_vivien_tan_xp_business_manager_siemens_healthineers_asean-24188.jpg)
